INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 178 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $247,000 | -84.0% | 9,641 | -91.9% | 0.00% | -100.0% |
| Q2 2019 | $1,543,000 | -57.3% | 118,884 | -59.9% | 0.00% | -50.0% |
| Q1 2019 | $3,610,000 | +2372.6% | 296,413 | +2831.9% | 0.00% | – |
| Q4 2017 | $146,000 | -95.8% | 10,110 | -95.4% | 0.00% | -100.0% |
| Q3 2017 | $3,442,000 | +379.4% | 218,088 | +393.4% | 0.01% | +500.0% |
| Q1 2017 | $718,000 | +7.6% | 44,200 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $667,000 | +138.2% | 44,200 | +531.4% | 0.00% | – |
| Q3 2015 | $280,000 | +9233.3% | 7,000 | +6900.0% | 0.00% | – |
| Q2 2015 | $3,000 | – | 100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |